IP Library › Granted Patent US 12,281,162
Granted Patent B2
US 12,281,162 · App. 17/859,973 · Granted Apr 22, 2025

Chimeric antigen receptors targeting GPRC5D

Inventors: Runsheng Li (Shanghai, CN); Wentao Huang (Shanghai, CN)
Assignee: LaNova Medicines Development Co., Ltd.
C07K16/2809A61P35/00A61K2039/505C07K2317/21C07K2317/31C07K2317/33C07K2317/565C07K2317/732C07K2317/734C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,281,162
App. No.
17/859,973
Granted
Apr 22, 2025
Kind
B2
Abstract

Provided are chimeric antigen receptors that include an antibody or fragment thereof having binding specificity to the human GPRC5D protein. The chimeric antigen receptors and immune cells expressing the chimeric antigen receptors are capable of targeting cancer cells expressing GPRC5D, and thus can be used to treat the cancer, in particular hematological cancer.

Claims (34)

1. An antibody-drug conjugate (ADC), comprising an antibody, or an antigen-binding fragment thereof, conjugated to a cytotoxin, wherein the antibody or the antigen-binding fragment thereof binds specifically to a human G-protein-coupled receptor family C group 5 member D (GPRC5D) protein and comprises:

a heavy chain variable region comprising a complementarity determining region 1 (HCDR1) amino acid sequence of SEQ ID NO: 42, an HCDR2 amino acid sequence of SEQ ID NO: 43, and an HCDR3 amino acid sequence of SEQ ID NO: 44; and

a light chain variable region comprising a complementarity determining region 1 (LCDR1) amino acid sequence of SEQ ID NO: 45, an LCDR2 amino acid sequence of SEQ ID NO: 46, and an LCDR3 amino acid sequence of SEQ ID NO: 47.

2. The ADC of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 9, 48, 49, or 50 or a variant having at least 95% sequence identity to SEQ ID NO: 9, 48, 49, or 50.

3. The ADC of claim 2 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 9, 48, 49, or 50.

4. The ADC of claim 1 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 10, 51, 52, or 53 or a variant having at least 95% sequence identity to SEQ ID NO: 10, 51, 52, or 53.

5. The ADC of claim 4 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 10, 51, 52, or 53.

6. The ADC of claim 1 , wherein

the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 9, 48, 49, or 50 or a variant having at least 95% sequence identity to SEQ ID NO: 9, 48, 49, or 50; and

the light chain variable region comprises the amino acid sequence of SEQ ID NO: 10, 51, 52, or 53 or a variant having at least 95% sequence identity to SEQ ID NO: 10, 51, 52, or 53.

7. The ADC of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 48 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 51.

8. The ADC of claim 1 , wherein the cytotoxin is a maytansinoid or an auristatin.

9. The ADC of claim 8 , wherein the cytotoxin is selected from the group consisting of maytansine, N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl) or N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine (DM1); monomethylauristatin-D (MMAD); monomethyl auristatin-E (MMAE); and monomethylauristatin-F (MMAF).

10. An antibody-drug conjugate (ADC), comprising an antibody, or an antigen-binding fragment thereof, conjugated to monomethyl auristatin-E (MMAE), wherein the antibody or the antigen-binding fragment thereof binds specifically to a human G-protein-coupled receptor family C group 5 member D (GPRC5D) protein and comprises:

a heavy chain variable region comprising a complementarity determining region 1 (HCDR1) amino acid sequence of SEQ ID NO: 42, an HCDR2 amino acid sequence of SEQ ID NO: 43, and an HCDR3 amino acid sequence of SEQ ID NO: 44; and

a light chain variable region comprising a complementarity determining region 1 (LCDR1) amino acid sequence of SEQ ID NO: 45, an LCDR2 amino acid sequence of SEQ ID NO: 46, and an LCDR3 amino acid sequence of SEQ ID NO: 47.

11. The ADC of claim 10 , wherein the ADC comprises a linker that connects MMAE to the antibody or the antigen-binding fragment thereof.

12. The ADC of claim 10 , wherein the ADC is a peptide having a drug to antibody ratio of 1 to 8.

13. The ADC of claim 12 , wherein the ADC is a peptide having a drug to antibody ratio of about 2 to about 4.

14. An antibody-drug conjugate (ADC), comprising an antibody, or an antigen-binding fragment thereof, conjugated to monomethyl auristatin-E (MMAE), wherein the antibody or the antigen-binding fragment thereof binds specifically to a human G-protein-coupled receptor family C group 5 member D (GPRC5D) protein and comprises:

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 48; and

a light chain variable region comprising the amino acid sequence of SEQ ID NO: 51.

15. The ADC of claim 14 , wherein the ADC is a peptide having a drug to antibody ratio of 1 to 8.

16. The ADC of claim 15 , wherein the ADC is a peptide having a drug to antibody ratio of about 2 to about 4.

17. A method of treating cancer, comprising:

administering to a patient having a hematological cancer, an antibody-drug conjugate (ADC), comprising an antibody, or an antigen-binding fragment thereof, conjugated to monomethyl auristatin-E (MMAE), wherein the antibody or the antigen-binding fragment thereof binds specifically to a human G-protein-coupled receptor family C group 5 member D (GPRC5D) protein and comprises:

a heavy chain variable region comprising a complementarity determining region 1 (HCDR1) amino acid sequence of SEQ ID NO: 42, an HCDR2 amino acid sequence of SEQ ID NO: 43, and an HCDR3 amino acid sequence of SEQ ID NO: 44; and

a light chain variable region comprising a complementarity determining region 1 (LCDR1) amino acid sequence of SEQ ID NO: 45, an LCDR2 amino acid sequence of SEQ ID NO: 46, and an LCDR3 amino acid sequence of SEQ ID NO: 47.

18. A method of treating cancer, comprising:

administering to a patient having a hematological cancer, an antibody-drug conjugate (ADC), comprising an antibody, or an antigen-binding fragment thereof, conjugated to monomethyl auristatin-E (MMAE), wherein the antibody or the antigen-binding fragment thereof binds specifically to a human G-protein-coupled receptor family C group 5 member D (GPRC5D) protein and comprises:

a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 48; and

a light chain variable region comprising the amino acid sequence of SEQ ID NO: 51.

19. The method of claim 17 , wherein the hematological cancer is multiple myeloma.

20. The method of claim 18 , wherein the hematological cancer is multiple myeloma.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2024
From: LI, RUNSHENG; HUANG, WENTAO
To: LANOVA MEDICINES DEVELOPMENT CO., LTD.
Reel/Frame 069183/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2023
From: LI, RUNSHENG; HUANG, WENTAO
To: LANOVA MEDICINES DEVELOPMENT CO., LTD
Reel/Frame 064259/0761 →
Priority Claims (1)
WO PCT/CN2021/070314 · Jan 5, 2021 · international
Continuity (3)
Continuation 17685029 · Mar 2, 2022
Continuation PCTCN2022070287 · Jan 5, 2022
Related Publication 20230203160A1 · Jun 29, 2023
References Cited (23)
US 10562968B2 · Attar et al. · 2020 [cited by applicant]
US 11485783B2 · Li et al. · 2022 [cited by applicant]
US 20180037651A1 · Attar et al. · 2018 [cited by applicant]
US 20190367612A1 · Chaen · 2019 [cited by applicant]
CN 111643676A · 2020 [cited by applicant]
EP 3581651A1 · 2019 [cited by applicant]
JP 2018524284A · 2018 [cited by applicant]
JP 2019527061A · 2019 [cited by applicant]
TW 201936641A · 2019 [cited by applicant]
WO 2016090329A2 · 2016 [cited by applicant]
WO 2016187220A2 · 2016 [cited by applicant]
WO 2018017786A2 · 2018 [cited by applicant]
WO 2018147245A1 · 2018 [cited by applicant]
WO 2019154890A1 · 2019 [cited by applicant]
WO 2020092854A2 · 2020 [cited by applicant]
WO 2020148677A1 · 2020 [cited by applicant]
Chari et al., “A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM… [cited by applicant]
International Search Report and Written Opinion for PCT/CN2022/070287 dated Apr. 7, 2022, 16 pages. [cited by applicant]
Kodama et al., “Anti-GPRC5D/CD3 Bispecific T Cell-redirecting Antibody for the Treatment of Multiple Myeloma”, MCT-18-1216R1, Molecular Cancer Therapeutics, Published online on Jul. 3, 2019, 34 pages. [cited by applicant]
Pillarisetti et al., “A T-cell-redirecting Bispecific G-protein-coupled Receptor Class 5 Member D x CD3 Antibody to Treat Multiple Myeloma”, Blood, Apr. 9, 2020, vol. 135, No. 15 pp. 1232-1243. [cited by applicant]
Smith et al., “GPRC5D is a Target for the Immunotherapy of Multiple Myeloma with Rationally Designed CAR T Cells”, Sci. Transl. Med., 11, eaau7746, 14 pages, Mar. 27, 2019. [cited by applicant]
Nishida H., “Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review”, Cancers, vol. 13, No. 11, May 31, 2021, 2712, pp. 1-31. [cited by applicant]
Supplementary European Search Report in European Patent Application No. 22736532.7, dated Apr. 11, 2024, 9 Pages. [cited by applicant]